| INTRODUCTION
Obesity is defined by the World Health Organization as a condition of excessive accumulation of body fat that causes serious damage to health. 1 This condition is continuously increasing in the general population and so also in patients eligible for liver transplantation (LT) in the USA. 2, 3 In fact, the percentage of obese US candidates undergoing liver transplantation increased from 21% to 32% in the periods 1988-1996 and 2001-2011 respectively. [4] [5] [6] In general, obesity is associated with numerous comorbidities and a higher risk of post-operative complications (respiratory [pneumonia, atelectasis, pulmonary embolism], cardiac [atrial fibrillation],
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infectious [nosocomial infections, wound infections] and surgical
[wound dehiscence]). 7, 8 However, there is no consensus in the literature as to the risk of specific complications related to obesity in liver transplantation. Currently, the American Association for the Study of Liver Disease, in accordance with the American Society of Transplantation, considers only morbid obesity (body mass index
[BMI]≥40 kg/m 2 ) as a relative contraindication for liver transplantation, since these patients seem to be exposed to a higher risk of post-transplant complications and mortality. 3 Similar considerations are reported by the European Association for the Study of the Liver, but in this case only post-operative infections and increased hospital and/or intensive care unit length of stay are mentioned as risk factors. 9 Nevertheless, the European guidelines state that patients with a BMI>35 should be carefully evaluated by a multidisciplinary team before being included in the waiting list. 9 On the other hand, there is a reasonable body of work demonstrating that patients with obesity who undergo general surgery actually do better in the long term when compared with normal weight individuals. In addition, we compared patients with BMI: 18.5-39.9 vs BMI≥40. In our analysis we excluded candidates with malnutrition (BMI<18.5), since this condition seems to increase post-transplant risks of complications and mortality. 11, 12 Using the above-mentioned selection criteria, 105 374 patients who underwent liver transplantation described in 22 cohort studies, mostly performed in the USA, were analysed.
2 | ME TH ODS
| Data sources and searches
Literature selection was performed in March 2017, focusing on studies comparing mortality and post-operative complications in patients assigned to different BMI categories, who underwent orthotopic liver transplantation. For this purpose, an electronic search of the literature was conducted using the online databases Cochrane library, PubMed, Scopus and Web of Science, entering the query terms ("body mass index" OR, "visceral adipose tissue" OR "fat mass" OR "obesity") AND "liver transplant*" AND ("complication" OR "morbidity" OR "outcome" OR "mortality" OR "survival" OR death* OR length of stay OR infection* OR vascular OR wound). Further relevant articles were hand-searched using the references of the selected studies.
| Study selection
Since we did not compare outcomes on the basis of treatment (liver transplantation), but on the basis of pre-defined categories (BMI 
| Data extraction and quality assessment
We conducted the articles selection according to a two-step approach, to evaluate whether they matched the eligibility criteria.
The first phase was based on titles and abstracts, and the second on full-text examination. This procedure was performed by two of the authors (VMT and PM), and the percentage of agreement demonstrated a high inter-rater reliability (93.4%). In addition, they independently extracted, classified and coded data, using standardised data extraction forms, based on the characteristics of the studies, population examined and outcomes. Two other authors (LG and MB), independently evaluated the methodological quality of each study and the quality assessment using the Newcastle Ottawa Scale for nonrandomised studies in meta-analyses. 13 In cases of studies analysing overlapping periods from the same transplantation registry, we considered only the study with the larger number of patients.
Finally, discrepancies in data extraction were resolved by introducing a third, experienced arbitrator (LG).
| Data synthesis and analysis
We performed different meta-analyses comparing various BMI cate- In addition, mean differences were computed for hospital and ICU length of stay. Finally, for each effect size, we calculated 95% CI, variance, standard error and statistical significance.
Then, single effect sizes of the primary studies were pooled to determine an overall effect size. For this purpose, we applied the random-effects model. 14, 15 The heterogeneity among studies was tested with Cochran Q and I 2 statistics. 16 A P value at Chi-Square test lower than 0.10 or I²>50% indicated substantial heterogeneity. 17 When adequate details were available, variables analyses were performed to assess the factors that could explain the observed heterogeneity. We tested year of publication as a continuous variable by meta-regression. 14 First, we applied Egger's regression method to estimate the asymmetry of the funnel plots, considering not statistically significant results as absence of publication bias. 18 All the above described statistical analyses were performed using two meta-analytic softwares: RevMan 5.3 (The Nordic Cochrane
Centre, Copenhagen, Denmark, Cochrane Library) 19 and our dedicated software. 14 
| RESULTS
The combined search of electronic databases identified 2132 articles ( Figure 1) . After a full-text analysis, 24 articles matched the eligibility criteria and were included in the meta-analysis. These studies enrolled a total number of 132 126, liver transplanted patients. Two articles 4, 20 analysed data from the same transplantation register (UNOS), in two overlapping periods, using different outcomes except for 1-year mortality. For this reason, only the 1-year mortality from the larger study was included in our analysis. 4 3.1 | Characteristics of the selected studies Table 1 BMI categories, too, were unevenly analysed and only in seven studies all BMI categories were considered.
| Outcome analyses
All the results obtained by the analysis of each outcome are summarised in Table 2 . Statistically significant results are also shown in Figure 2 and Figures S1-S3.
| Mortality following liver transplantation
In all categories of obesity, 30-day mortality resulted significantly higher compared to the values in normal/overweight patients (BMI: Only class III obesity showed a higher mortality rate at 1 year, as compared to controls (OR=1.38; 95% CI: 1.00, 1.92) ( Figure S1 ). In this analysis we found a minor heterogeneity. The year of publication was a predictive factor for heterogeneity in the comparison between controls and class II obesity, showing a direct relationship (b=0.50).
The 3-year mortality resulted significantly higher only when comparing patients with a BMI>30 to control patients (OR=1.60; 95% CI: 1.07, 2.40) (Table 2, Figure S2 ). However, considerable heterogeneity among studies was observed in this context. The metaregression analysis demonstrated an inverse relationship between heterogeneity and the year of publication (b=À0.80) in the comparison between controls and class III obesity.
The last meta-analysis showed a significantly higher 5-year mortality in the BMI>30 and >40 subgroups when compared to normal/ overweight patients (Table 2, Figure S2 ). This effect was greater in patients with a BMI≥40 (OR=1.48; 95% CI: 1.03, 2.14), a result also confirmed by the comparison of class III obesity with BMI: 18. 
| Quality assessment and risk of bias
The quality assessment of the studies included in our meta-analysis indicates that the selection and representativeness of patients, the ascertainment of exposure and the outcomes of interest were optimal in 19 studies, while in the remaining five studies only the representativeness of the exposed cohort was insufficient. As far as comparability is concerned, seven studies did not provide all the selected outcomes, while the judgement of the outcome was suboptimal in 17 studies since the assessment of outcomes was not linked to an institutional record (Table S1 ).
As expected, the Egger's test approach identified publication bias when the analysis was based on a limited number of studies. In particular, publication bias were found for post-operative mortality at 30 days in BMI categories 35-39.9 and >40, at 2 years in BMI >40. Again, publication bias were observed for post-operative complications when comparing a BMI≥30 and >40 vs normal/overweight patients (Table 2) .
| DISCUSSION
The most recent guidelines published by the American Association for the Study of Liver Disease and American Society of Transplantation, as well as the British Transplant Society guidelines, indicate only LT candidates with severe obesity (BMI≥40) as exposed to higher risks of mortality after liver transplantation. However, they grade this recommendation as uncertain and requiring further research to estimate the clinical effect. 3, 42 This conclusion is also drawn in some recent reviews on this topic. [43] [44] [45] On the other hand, the literature data on mortality risk in candidates with classes I and II obesity are weak. 9, 42 In practice, morbidly obese patients appear to be relatively disadvantaged in their access to LT under current practice.
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Nair (2002) Leonard ( ), known to suffer higher mortality risks. 6, 46 This allowed us to draw different conclusions compared to the most recent meta-analysis that analysed only the mortality risk, including 13 studies. 47 In fact, the authors suggest that the BMI does not specifically impact patient survival, but at the same time report a reduced survival in obese recipients in a subanalysis including a limited number of patients. In addition, this study included malnourished subjects in the control group, and arbitrarily excluded overweight recipients from the control group.
Our analysis clearly shows that LT candidates with a BMI≥40
had a significantly higher mortality risk at 30 days, 1, 2 and 5 years after transplantation as compared to normal/overweight patients, while the results at 3 years did not reach statistical significance.
However, the data at 30 days are weak, being based on only two studies with opposite results, whereas the results at 1 and 2 years are more robust. Moreover, the analysis at 5 years warrants special comment. It is clear that obesity carries an increased risk of mortal- Interestingly, the data on post-operative complications demonstrated that LT candidates with a BMI≥30 are significantly exposed to a higher risk as compared to normal/overweight subjects. However, when the single classes of obesity were considered, statistical significance was only observed in class I obesity, although higher OR values were found in the other two classes (BMI: 35-39.9 and ≥40).
The loss of significance in the latter categories of obesity was probably due to the smaller number of studies and patients included in the analysis as compared to the BMI≥30 and BMI: 30-34.9 categories. Moreover, the specific evaluation of cardiopulmonary complications confirmed that a BMI≥30 is associated to a higher risk of post-operative complications.
Finally, the evaluation of hospital and ICU length of stay led to the conclusion that only the former parameter was significantly longer in the BMI≥30 patients as compared to controls.
The confidence of our results is highest at 30 days, 1 and 2 years since several studies with a low heterogeneity and practically without publication bias indicated a higher risk of post-transplant mortality for patients with a BMI>30 at 30 days and for patients with a BMI≥40 at all the three time-periods (OR: 1.36, 1.34 and 1.46 respectively). Meta-regression analysis shows that more recent studies suffered from a lower degree of heterogeneity, which is an expected finding due to improvements in clinical procedures and data collection.
As regards the clinical implications of our analysis, class III obesity is a factor with a negative impact on patient survival after liver transplantation. 48 On the other hand, a higher risk of post-operative complications, including cardiopulmonary complications, is already observed in lower categories of obesity (BMI≥30) as compared to normal/overweight patients.
Before drawing final conclusions, it should be underlined that the BMI has several limitations since it does not take into account body composition, gender, age, and consequently, the significant difference in fat mass between men and women. 48 Moreover, it does not consider an increase in extracellular fluids, as in cases of oedema or ascites. Another aspect to consider could be the potential confounding effect due to the inclusion of both prospective and retrospective studies. In addition, recent studies suggest that obesity might be associated with a decreased muscle mass, delineating the new scenario of sarcopenic obesity, a condition that could lead to a reconsideration of the concept of an obesity-related risk. [49] [50] [51] Finally, the study by Wong et al. 52 suggests that diabetes rather than obesity is associated to post-transplant mortality, a consideration that seems to be confirmed by a more recent study, although the latter reported adjusted OR based on several different additional parameters. 41 Considering the positive trend of obesity and NASH-related cirrhosis in the last decades, the policy of transplant centres should include the development of new methods for the assessment of body composition, integrating the pre-transplant BMI evaluation, and implementing strategies to favour weight loss in liver transplant candidates.
The present study has some limitations. The lack of homogeneous data on graft survival did not allow us, nor probably others, 47 to analyse this outcome. In addition, we did not take into account the influence of a correction of BMI according to the volume of ascites, since only three studies evaluated this aspect 26, 36, 47 and one of them used liver transplant recipients with a BMI 15-25 as controls; 47 another reported that after the BMI correction for ascites was considered, there was no significant increase in mortality in obese patients as compared to controls, but the same authors state that ascites per se was independently associated with a higher risk for mortality, and report higher volumes of ascites in controls as compared to obese recipients (2.2AE3.0 vs 0.6AE1.4). 36 The last study reported no difference in patient survival between the different groups, although overweight and obese patients had a significantly increased morbidity. 26 Finally, for theoretical reasons, a meta-analytic approach is based on raw data unless all studies included apply OR or HR adjusted for the same parameters. Therefore, we could not evaluate other confounding factors such as diabetes, per se a postoperative risk factor.
The language restriction to English, which was made a priori, could have limited our analysis, but it should be taken into account that the majority of data on liver transplant patients are reported in North America and European data registries. Another important point is that, as reported by Segev et al., 46 a longer permanence on the waiting list of obese patients and/or the variability in selection BARONE ET AL.
| 243 bias between programmes for various thresholds of obesity, cannot be captured or quantified by the various studies considered in our analysis. Finally, it is possible that the more widespread transplant expertise and improved medical management may have had an impact on the risk associated with obesity over the last decade as compared with earlier periods.
| CONCLUSIONS
Our analysis suggests that class III obesity poses a significantly increased mortality risk after liver transplantation and that, together with those in the other two classes of obesity, these patients are exposed to a higher risk of post-operative complications.
ACKNOWLEDGEMENT
Declaration of personal interests: All authors declare no conflict of interest (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants/patents received or royalties).
AUTHORSHIP
Guarantor of the article: Michele Barone. 
R E F E R E N C E S

